Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M5717 First-in-Human and Malaria Challenge Study
NCT03261401Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cabamiquine in Plasmodium falciparum malaria (13 arms), sponsored by Merck KGaA. Primary endpoints: Treatment Emergent Adverse Events, Clinically Significant Changes in Laboratory Assessments and 11 more. Started Sep 2017; status: completed.
02
Drugs
cabamiquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT03261401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261401.